Targeting apoptosis in cancer therapy
For over three decades, a mainstay and goal of clinical oncology has been the development of therapies promoting the effective elimination of cancer cells by apoptosis. This pro...
Publications
9 shownSupplementary Table S1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>Supplementary Table S1. Dose-escalation Schema</p>
Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day ...
Table 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>Baseline patient characteristics.</p>
Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>Supplementary Table S2. Representativeness of Study Participants</p>
Data from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<div>AbstractPurpose:<p>Metastatic castration-resistant prostate cancer with homologous recombination (HR) deficiency (HRD) is sensitive to PARP inhibitors (PARPi). ...
Figure 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>Swimmer plot showing treatment duration on study for all patients. Genomic alterations in the homologous recombination DNA repair and PI3K/AKT/mTOR pathways are noted f...
Table 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>HRD pathogenic genomic alterations.</p>
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 9
- Citations
- 2,396
- Institution
- Brown University
External Links
Identifiers
- ORCID
- 0000-0002-5468-1126
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.